Welcome to our dedicated page for NEKTAR THERAPEUTICS SEC filings (Ticker: NKTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nektar Therapeutics filings document the regulatory record of a Delaware clinical-stage biotechnology issuer with common stock listed on the Nasdaq Capital Market under NKTR. The company's 8-K reports cover financial results, Regulation FD clinical disclosures for rezpegaldesleukin, material definitive agreements, underwriting arrangements, at-the-market equity distribution mechanics, and shelf-registration-related offerings.
Proxy materials describe annual meeting matters, director elections, equity incentive plan authorization, auditor ratification, executive compensation votes, and governance procedures. Nektar's filing record also reflects capital-structure disclosures for common stock and pre-funded warrants, clinical-stage pipeline risks, research and development funding needs, and public-company controls tied to its immunology drug development business.
Nektar Therapeutics filed an 8-K stating it has furnished a press release announcing its financial results for the quarter ended September 30, 2025. The company attached the press release as Exhibit 99.1 titled “Nektar Therapeutics Reports Third Quarter 2025 Financial Results.”
The information is furnished under Item 2.02 and is expressly stated as not deemed “filed” under Section 18 of the Exchange Act and not incorporated by reference into other SEC filings. Nektar’s common stock trades on the Nasdaq Capital Market under the symbol NKTR.
Nektar Therapeutics director Roy A. Whitfield was granted 8,000 stock options on 09/30/2025. The option award has an exercise price of $56.90 and an expiration date of 09/29/2033. The filing shows the options are directly beneficially owned by the reporting person and will vest in substantially equal monthly installments over the one-year period beginning on September 30, 2025.
NEKTAR THERAPEUTICS (NKTR) Form 4 summary: Director Greer R. Scott received a non-derivative award in the form of a stock option grant on 09/30/2025 for 8,000 options with a stated conversion/exercise price of $56.90. The reported option is exercisable beginning 09/29/2033 and the filing shows 8,000 shares benefically owned following the transaction, held directly. The filing notes the option vests in substantially equal monthly installments over the one-year period beginning on 09/30/2025. The form was signed by an attorney-in-fact on 10/01/2025. The document discloses a standard director compensation award rather than a sale or disposition.
Diana Brainard, a director of Nektar Therapeutics (NKTR), was granted an option for 8,000 shares on 09/30/2025. The option has an exercise price of $56.90 and is recorded as a direct holding of 8,000 underlying shares following the transaction. The option vests in substantially equal monthly installments over the one-year period beginning on September 30, 2025, and the instrument shows an exercisable/expiration date of 09/29/2033. The Form 4 is signed by an attorney-in-fact on 10/01/2025, reporting the acquisition (code A) of the derivative security.
Jeffrey Robert Ajer, a director of Nektar Therapeutics (NKTR), acquired a derivative grant of 8,000 stock options on 09/30/2025. The options have a stated conversion/exercise price of $56.9 and the filing reports 8,000 underlying shares of common stock. The filing notes the options vest in substantially equal monthly installments over the one-year period beginning on September 30, 2025. The form indicates an expiration/related date of 09/29/2033 and shows the shares are beneficially owned directly following the transaction. The Form 4 was signed by an attorney-in-fact on 10/01/2025.
Nektar Therapeutics filed a current report describing new clinical data from its ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin in atopic dermatitis. The company posted a slide deck on its website with additional efficacy and safety information and furnished it as Exhibit 99.1. Nektar also issued a press release about the new data and a late-breaker oral presentation at EADV 2025, furnished as Exhibit 99.2. These materials are being furnished, not filed, which limits their use under certain securities law provisions.
Insider sales by Nektar Therapeutics CEO and Director Robin W. Howard are reported on Form 4. On 09/09/2025 Mr. Howard sold a series of common stock lots under a disclosed Rule 10b5-1 trading plan: 2,100 shares at a weighted average price of $45.16, 1,200 shares at $46.41, 2,156 shares at $47.49, and 1,210 shares at $48.18. The filings show his beneficial ownership declined through the sequence from 53,908 shares to 49,342 shares after the last reported sale; an indirect holding of 28 shares is listed as held by his spouse. The report was executed under an established trading plan and the filer states willingness to provide trade-level details on request.
Form 144 filed for NKTR (Nektar Therapeutics) reports a proposed sale of 6,666 common shares by an insider through Fidelity Brokerage Services on 09/09/2025 on NASDAQ, with an aggregate market value of $311,204.76. The filing lists total shares outstanding as 19,018,573. The shares to be sold match the sum of restricted stock vesting awards acquired between 05/15/2016 and 11/15/2021 that total 6,666 shares and were granted as compensation. The seller is identified as Howard Robin at the provided address. Recent dispositions by the same person in the prior three months total 14,905 shares for gross proceeds of $518,026.81 across four sales dated 08/19/2025 through 09/05/2025. The filing does not include the issuer name, CIK, or certain contact details in the provided text.
Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics (NKTR), reported four sales of company common stock on 09/04/2025 under a Rule 10b5-1 trading plan. The transactions disposed of 1,721 shares in total (793; 432; 189; 307) at weighted average prices of $32.43, $33.60, $34.41, and $35.69 respectively, with execution price ranges disclosed for each lot. Following these sales, the reporting person beneficially owned 17,462 shares (direct ownership). The filing indicates the trades were executed pursuant to a pre-established plan and the filer offers to provide full trade-by-trade details on request.
Robin W. Howard, President & CEO and director of Nektar Therapeutics (NKTR), sold a total of 11,832 shares of common stock under a Rule 10b5-1 trading plan on September 4-5, 2025. The sales were reported in several block transactions with weighted-average prices reported at $32.37, $33.54, $34.40, $35.80, $37.87, $38.82 and $39.89. Following these dispositions the reporting person beneficially owned 56,008 shares directly; an additional 28 shares are held indirectly by the reporting person’s spouse. The filer states the transactions were effected pursuant to a 10b5-1 plan and provides price ranges for each grouped trade.